LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

First-Ever Blood-Powered Chip Offers Real-Time Health Monitoring

By LabMedica International staff writers
Posted on 25 Jun 2024
Print article
Image: The proposed self-powered, millifluidic lab-on-a-chip device to determine blood conductivity (Photo courtesy of Advanced Materials/DOI: 10.1002/adma.202403568)
Image: The proposed self-powered, millifluidic lab-on-a-chip device to determine blood conductivity (Photo courtesy of Advanced Materials/DOI: 10.1002/adma.202403568)

Metabolic disorders such as diabetes and osteoporosis are rapidly increasing globally, especially in developing countries. Diagnosing these conditions generally requires blood tests; however, in remote areas with insufficient healthcare infrastructure, many individuals remain undiagnosed and untreated. Traditional diagnostic methods are invasive and labor-intensive, making real-time monitoring impractical, particularly in rural settings. Blood electrical conductivity, which reflects the concentration of key electrolytes like sodium and chloride ions, is crucial for diagnosing various health issues. These electrolytes play a vital role in many physiological processes, but measuring blood conductivity faces challenges such as electrode polarization, limited access to samples, and maintaining consistent blood temperature. Moreover, measuring conductivity at frequencies below 100 Hz, essential for a deeper understanding of blood's electrical properties and underlying biological functions, presents additional difficulties. Researchers are now advancing a novel device that generates electricity from blood to measure its conductivity, thereby facilitating medical care anywhere.

A research team at the University of Pittsburgh (Pittsburgh, PA, USA) has developed a portable millifluidic nanogenerator lab-on-a-chip device that can measure blood conductivity at low frequencies. This device uses blood as a conductive agent within a triboelectric nanogenerator (TENG). The TENG system harnesses mechanical energy from the blood and converts it into electricity through triboelectrification, where electron transfer occurs between contacting materials during movements such as compression or sliding.

This electron transfer and subsequent charge separation create a voltage difference that propels an electric current. The device measures the voltage generated under specific loading conditions to ascertain the blood's electrical conductivity. Its self-powering capability allows for the miniaturization of this innovative blood-based nanogenerator. The team employed AI models to predict blood conductivity directly from the voltage patterns produced by the device, and comparative tests with traditional methods have validated its accuracy. This breakthrough paves the way for deploying diagnostics directly to people's homes. Additionally, blood-powered nanogenerators could operate internally, utilizing the body's own blood chemistry for self-powered diagnostics.

“As the fields of nanotechnology and microfluidics continue to advance, there is a growing opportunity to develop lab-on-a-chip devices capable of surrounding the constraints of modern medical care,” said Amir Alavi, assistant professor of civil and environmental engineering at Pitt’s Swanson School of Engineering. “These technologies could potentially transform healthcare by offering quick and convenient diagnostics, ultimately improving patient outcomes and the effectiveness of medical services.”

Related Links:
University of Pittsburgh

Gold Member
Veterinary Hematology Analyzer
Exigo H400
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Troponin I Test
Quidel Triage Troponin I Test
New
Centrifuge
Hematocrit Centrifuge 7511M4

Print article

Channels

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.